explore -WSS

explore

author：leisure time 2025-09-28 15:56:50 - browse：132

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

Fresh off of the news that its drug Wegovy may not just help people lose weight, but could also lower cardiac risks, Novo Nordisk doubled down on its obesity drug pipeline Thursday, acquiring a small Canadian biotech with a new approach to weight loss.

Novo will spend up to $1 billion to buy Inversago Pharma, which is developing an oral obesity drug that targets the cannabinoid receptor CB1. It’s the second big obesity acquisition this year, following Eli Lilly’s move to purchase startup Versanis Bio.

Drugs like Wegovy are in a class called GLP-1 drugs, which mimic the effects of the glucagon-like peptide 1 hormone that help people feel full by targeting the hormone’s receptors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Does aspartame cause cancer? What new WHO guidance says

WSS

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Medicare wants to send $9 billion to 340B hospitals

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Global childhood vaccinations edge closer to pre

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

hotspot

explore

explore

Tori Bowie and the unacceptable rates of Black maternal death

Care demand spikes challenge UnitedHealth’s provider arm

Heart attack and stroke risk calculators need revising

Europe sees delivery challenges ahead on Alzheimer's therapies

What does generative AI mean for health care? We asked experts

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Biden targets hefty hospital 'facility fees' that often surprise patients

How one medical school became remarkably diverse

Celiac disease study examines precisely how gluten triggers injury

knowledge

Presidential fundraising highlights so far: Trump brings in more than DeSantis

Federal judge rules Oregon’s tough new gun law is constitutional

Grail faces three suits alleging harassment, retaliation

US sending controversial cluster munitions to Ukraine until other ammo is ready: Kirby

Recent heat wave in the Mediterranean caused by climate change: Study

The aspartame in Diet Coke probably isn’t giving you cancer

hotspot

hotspot

focus

explore